TETEC AG
TETEC AG is a Reutlingen-based German biotechnology company that develops and manufactures autologous cell-based MACT cartilage regeneration products (NOVOCART 3D and NOVOCART Inject) and CDMO services, selling to hospitals and orthopedic clinics treating patients with focal knee cartilage defects.
- Company typePrivate
- Founded2000
- HeadquartersReutlingen, Germany
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What TETEC AG does
TETEC AG is a German Aktiengesellschaft headquartered in Reutlingen that develops and manufactures autologous cell-based therapies for the biological regeneration of cartilage defects in the human musculoskeletal system. The company was founded in 2000 as a spin-off from the Natural and Medical Sciences Institute and the Berufsgenossenschaftliche Unfallklinik Tübingen, and has accumulated over 20 years of clinical experience with more than 30,000 individual products manufactured and over 7,000 Injectable MACT procedures performed in Germany since 2008.
The core product portfolio consists of two matrix-associated autologous chondrocyte transplantation (MACT) systems: NOVOCART 3D, a biphasic collagen matrix seeded with the patient's own chondrocytes for focal cartilage defects of 2–10 cm²; and NOVOCART Inject, a PEG-albumin-hyaluronic acid hydrogel-based injectable system that self-sets in 1–3 minutes and supports minimally invasive arthroscopic delivery for defects of 2–12 cm². Manufacturing takes place in GMP-certified cleanrooms using closed isolator systems under Paul-Ehrlich-Institut oversight, with quantitative PCR-based cell and molecular biology quality control for each product. An EMA centralized approval application for the gel-based ATMP was submitted in December 2023.
TETEC monetizes through one-time per-patient sales of its ATMP products to hospitals, orthopedic clinics, and certified treatment centers in Germany (reimbursed in part by the German public health insurance system, GKV), supplemented by contract development and manufacturing services for other ATMP developers (TETEC CDMO, now rebranded as Octane CDMO following the 2024 acquisition). The company serves orthopedic surgeons, sports medicine physicians, and patients with focal knee cartilage defects, using a direct enterprise field sales motion supplemented by conference participation, a DocCheck-secured physician portal, and dedicated customer service and tissue harvesting teams. In June 2024, TETEC was acquired by Octane Biotherapeutics (BioTx), part of Canada's Octane Medical Group, alongside Aesculap Biologics LLC in the United States, with planned integration of Octane's Cocoon automated bioreactor for scalable cell therapy production.
TETEC AG firmographics
Firmographics- Name
- TETEC AG
- Legal name
- TETEC AG
- Website
- https://tetec-ag.de
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Short description
- TETEC AG is a Reutlingen-based German biotechnology company that develops and manufactures autologous cell-based MACT cartilage regeneration products (NOVOCART 3D and NOVOCART Inject) and CDMO services, selling to hospitals and orthopedic clinics treating patients with focal knee cartilage defects.
- Ownership category
- akta.pro rank
TETEC AG industry classification
Industry- Product category
- Orthobiologics and Cell-Based Cartilage Regeneration Therapies
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where TETEC AG is headquartered
LocationHeadquarters
- HQ city
- Reutlingen
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
TETEC AG business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- ATMP Product Sales (NOVOCART 3D and NOVOCART Inject): Sale of cell-based tissue engineering products for cartilage regeneration. Products are manufactured individually for each patient and sold to hospitals and orthopedic clinics. Revenue from product sales to healthcare providers.
- CDMO Services (via Octane CDMO): Contract development and manufacturing services for other ATMP developers, including process translation to GMP environment, clinical specimen manufacturing, clinical trial coordination, and regulatory approval support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time/ perpetual license | Injectable MACT covered by German public health insurance |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
TETEC AG product offering
Product offeringCore offering
TETEC AG develops and manufactures autologous cell-based tissue engineering products for the biological regeneration of focal cartilage defects in the human musculoskeletal system. Its core offerings are two matrix-associated autologous chondrocyte transplantation (MACT) products — NOVOCART 3D (collagen matrix scaffold) and NOVOCART Inject (injectable hydrogel) — individually manufactured for each patient and sold to hospitals and orthopedic clinics. The company also provides CDMO services for Advanced Therapy Medicinal Product (ATMP) developers.
Product overview
TETEC AG offers two distinct autologous cell-based cartilage regeneration products: NOVOCART 3D (a biphasic collagen scaffold-based MACT system for defects 2-10 cm²) and NOVOCART Inject (an injectable hydrogel-based MACT for defects 2-12 cm²). Both products use the patient's own cultivated chondrocytes to support cartilage repair in focal knee defects. The company also operates TETEC CDMO (now rebranded as Octane CDMO), providing contract development and manufacturing services for ATMP developers. The product portfolio is complemented by the planned integration of Octane's Cocoon automated bioreactor for scalable cell therapy production.
Differentiator
Problem solved
Functional benefit
Products and services
- NOVOCART 3D A biphasic collagen matrix scaffold seeded with the patient's own cartilage cells (chondrocytes), used for matrix-associated autologous chondrocyte transplantation (MACT) to treat focal knee cartilage defects ranging from 2 cm² to 10 cm². Sold to hospitals and orthopedic clinics and individually manufactured for each patient.
- NOVOCART Inject An injectable matrix-associated autologous chondrocyte transplantation product combining the patient's cartilage cells with a PEG-albumin-hyaluronic acid hydrogel that self-sets in 1–3 minutes, securing the graft in place. Indicated for defects from 2 cm² to 12 cm² and delivered arthroscopically with operating times of 15–40 minutes. Sold to hospitals and orthopedic clinics.
- TETEC CDMO (now Octane CDMO) Contract development and manufacturing organization services for Advanced Therapy Medicinal Product (ATMP) developers, including process translation to GMP environment, clinical specimen manufacturing, clinical trial coordination, regulatory approvals, and ATMP registration support. Delivered from the Reutlingen GMP-certified cleanroom facility.
Quantifiable outcome
- Over 90% success rate reported in 10+ year follow-up studies for MACT procedures
- +3 more outcomes
Companies that use TETEC AG
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
TETEC AG technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TETEC AG partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, former and minor.
- Octane Medical GroupcoreOctane Medical Group acquired TETEC AG in June 2024 as part of acquiring B. Braun's global orthobiologics business. TETEC became part of Octane Biotherapeutics (BioTx), combining TETEC's ATMP expertise with Octane's automated bioreactor technology (Cocoon). This integration enables transition from manual to automated cell production, potentially reducing costs while increasing quality and scalability.
- B. BraunformerB. Braun was the former parent company of TETEC through Aesculap Inc. TETEC originated from the biologics business of Aesculap. B. Braun sold its orthobiologics business to Octane Medical Group in June 2024. Dr. Jens von Lackum stated this sale was part of B. Braun's strategic focus on the Operating Room.
- Natural and Medical Sciences InstitutecoreTETEC emerged as spin-off from the Natural and Medical Sciences Institute in 2000. Continues to maintain close collaborations with this local innovation hub. Joint research and development activities in tissue engineering and cell therapy.
- University of TübingencoreResearch partnership rooted in TETEC's origin story as spin-off from Berufsgenossenschaftliche Unfallklinik Tübingen. Ongoing clinical research collaborations and university partnerships for cartilage regeneration development.
- BioRegio STERNminorTETEC is part of the BioRegio STERN biotech network, which includes 120 medtech companies and 110 biotech companies. Network provides innovation ecosystem and collaborative opportunities in the Stuttgart/Tübingen region.
- Aesculap Biologics, LLCcorePart of the same orthobiologics acquisition as TETEC by Octane Medical Group. Aesculap Biologics LLC in the United States and TETEC AG in Germany together form the orthobiologics platform acquired from B. Braun, including NOVOCART product portfolio.
- Cocoon Bioreactor (Octane)coreOctane's proprietary automated cell production system. TETEC plans to integrate Cocoon for transitioning from current manual production to full automation. This first-of-its-kind automated production system for personalized cell therapies enables precise control and scalability.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
TETEC AG competitors and assessment
Company assessmentBroad incumbents
- Zimmer Biomet: Zimmer Biomet offers orthobiologics including DeNovo NT and cartilage repair technologies within a large joint reconstruction franchise. Comparable broad incumbent operating in the same cartilage/sports medicine clinical workflows as TETEC.
- Arthrex: Arthrex is a major orthopedics and sports medicine device company with cartilage and biologics offerings. Comparable as a broad incumbent serving the same orthopedic surgeon channel through which TETEC sells NOVOCART.
- Smith+Nephew: Smith+Nephew sells cartilage repair and orthobiologics products (e.g., CartiKit, REGENETEN) alongside a broad sports medicine portfolio. Comparable broad incumbent whose portfolio overlaps with TETEC's cartilage regeneration focus.
- Stryker Corporation: Stryker operates a major orthopedics franchise with sports medicine and cartilage-related products. Comparable broad incumbent competing for the same hospital procurement budgets and surgeon mindshare as TETEC.
Emerging players
- LifeNet Health: LifeNet Health provides allograft and orthobiologics solutions, including cartilage allografts, for orthopedic surgeons. Comparable as an emerging orthobiologics competitor offering off-the-shelf alternatives to autologous chondrocyte transplantation.
- Medipost Co., Ltd. Medipost markets Cartistem, an allogeneic umbilical cord blood MSC product for cartilage regeneration. Comparable emerging alternative modality directly competing for the same cartilage defect indication with an off-the-shelf delivery model.
- Cook Medical: Cook Medical's regenerative medicine arm includes orthobiologics and cartilage repair devices. Comparable as a focused orthobiologics player with overlap in the cartilage repair and sports medicine surgeon channel.
Others
- Lonza Group: Lonza is a leading global CDMO with significant cell and gene therapy manufacturing capacity. Comparable to TETEC's CDMO arm (now Octane CDMO) as an adjacent ATMP contract manufacturing service provider rather than a direct product competitor.
Direct peers
- Geistlich Pharma: Geistlich manufactures Chondro-Gide, a collagen matrix widely used in matrix-associated chondrocyte transplantation. Comparable as a scaffold-supplier partner/competitor whose matrix technology can be paired with autologous chondrocytes similar to NOVOCART 3D.
- Vericel Corporation: Vericel develops and markets MACI, an autologous cultured chondrocyte product for cartilage defect repair. Direct competitor to TETEC's NOVOCART franchise, with EU centralized approval already in hand - the most relevant comparable in autologous cartilage cell therapy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
TETEC AG social profiles
Digital presenceTETEC AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
TETEC AG leadership team
Management profileNumber of profiles
Profiles6 records
TETEC AG subsidiaries and ownership
Company hierarchySubsidiaries1 record
TETEC AG funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TETEC AG M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TETEC AG
What does TETEC AG do?
TETEC AG develops and manufactures autologous cell-based tissue engineering products for the biological regeneration of focal cartilage defects in the human musculoskeletal system. Its core offerings are two matrix-associated autologous chondrocyte transplantation (MACT) products — NOVOCART 3D (collagen matrix scaffold) and NOVOCART Inject (injectable hydrogel) — individually manufactured for each patient and sold to hospitals and orthopedic clinics. The company also provides CDMO services for Advanced Therapy Medicinal Product (ATMP) developers.
Is TETEC AG a public or private company?
TETEC AG is a private company. It is classified as corporate owned and is currently operating.
When was TETEC AG founded?
TETEC AG was founded in 2000.
Where is TETEC AG based?
TETEC AG is headquartered in Reutlingen, Germany, in the Europe region.
How does TETEC AG make money?
Two revenue lines are on record. ATMP Product Sales (NOVOCART 3D and NOVOCART Inject) is the primary driver. The others are CDMO Services (via Octane CDMO).
Who are TETEC AG's main competitors?
Broad incumbents on record are Zimmer Biomet, Arthrex, Smith+Nephew and Stryker Corporation. Emerging players are LifeNet Health, Medipost Co., Ltd. and Cook Medical. Lonza Group is listed as an others. Direct peers are Geistlich Pharma and Vericel Corporation.
Does TETEC AG have an API?
No public API is recorded for TETEC AG.
What industry is TETEC AG in?
TETEC AG's product category is Orthobiologics and Cell-Based Cartilage Regeneration Therapies. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 3842.